drugset / Trial / NCT04535687

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

NCT04535687

NaSingle-groupOpen-labelTreatment

Summary

This trial aims to prospectively assess the safety and efficiency of Fluzoparib in metastatic non-clear cell renal cell carcinoma

Timeline

Start
2020-12-17
Primary completion
2023-06-12
Completion
2023-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluzoparib Small molecule

Indications